In the present study, all PPMS subjects, treated and untreated, showed an increase in FOXP3 expression on CD4+CD25high and also CD4+CD25+ Tregs compared with HCs, without significant differences between treated and untreated PPMS subjects. This evidence concerns the gene FOXP3 and primary progressive multiple sclerosis.